Alexion shares sink after Soliris fails Phase II testing; Eli Lilly names new senior VP to corporate business development unit;

@FiercePharma: ICYMI yesterday: New study clears Merck's blockbuster Gardasil of MS risk. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Valneva picks up J&J's cholera vaccine--and some forthcoming competition. More | Follow @CarlyHFierce

> Alexion Pharmaceuticals ($ALXN) said its Soliris blood-clotting treatment did not meet its goals in a Phase II clinical trial, sending the company's shares into a downward spiral. More

> Eli Lilly ($LLY) promoted Darren Carroll to senior vice president of its corporate business development unit. Story

> A Delaware judge ordered Siga Technologies to pay PharmAthene $113.1 million in damages in a licensing dispute over Siga's antiviral smallpox drug Tecovirimat. More

> Horizon Pharma rounded out 2014 with an estimated $290 million in revenue thanks to standout performances of pain pills Duexis and Vimovo, and analysts are forecasting more sales success in the coming year. Story

> GW Pharmaceuticals ($GWPH) and Otsuka Pharmaceutical revealed that their cannabis-based drug Sativex did not show any statistically significant difference than a placebo in the first of three Phase III trials. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Alere snags first FDA CLIA waiver for molecular influenza test. Article | Follow @FierceMedDev

@EmilyWFierce: Hedge fund exec aims new legal weapon at Big Pharma's 'evergreened' patents. Story | Follow @EmilyWFierce

> 23andMe's $60M deal with Genentech shows an alternative path forward for diagnostics companies. News

> FDA lifts import restriction on Hospira as it aims to reinvigorate its infusion pumps. Article

Biotech News

@FierceBiotech: Biogen Idec's remyelination drug raises hopes--and some fears--in Phase II. Story | Follow @FierceBiotech

@JohnCFierce: Anybody who says that statistical significance is not expected in a study is playing defense for a stock. | Follow @JohnCFierce

@DamianFierce: No FDA panel scheduled for Pizer's palbociclib, which $PFE hopes to get approved as Ibrance before April deadline. More | Follow @DamianFierce

> Novartis clears an FDA hurdle with its pioneering biosimilar of Amgen's Neupogen. News

> Atlas seedling banks $35M to feel out the future of immuno-oncology. Story

Vaccines News

> Pfizer's growth spurt continues with pickup of Switzerland's Redvax. Report

> Swiss trial of Merck/NewLink Ebola vaccine resumes at lower dose. Article

> Valneva picks up J&J's cholera vaccine--and some forthcoming competition. Story

> No link between Merck's Gardasil and MS risk, study shows. Item

> Johnson & Johnson is third to bring Ebola vaccine to trials, but is it too late? More

Pharma Manufacturing News

> Impax Labs overcomes manufacturing issues to get Parkinson's drug approved. More

> Arena, Eisai have to recall nearly 122,000 bottles of Belviq over labeling glitch. Article

> France and Italy ban products from Indian companies. More

> Drugmakers ask Supreme Court to squelch California drug takeback law. Story

> China regulator promises action to fix 'grim' drug safety situation. Article

And Finally… A new study found that monthly injections of testosterone could shrink tumors in patients with prostate cancer, delivering a surprise to researchers. Story

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.

Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.